ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1516348
This article is part of the Research TopicRecent Advances in Radiation Oncology for the Management of Thoracic MalignanciesView all 15 articles
Development of a Predictive Model for Radiation Pneumonitis Based on Plasma Exosomal miR-200b-5p
Provisionally accepted- 1Department of Radiation Oncology, Changzhou jintan first people's hospital, Changzhou, China
- 2Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
- 3Department of Radiation Oncology, The Affiliated Taizhou Hospital, Wenzhou Medical University, Taizhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aims to explore the association between plasma exosomal miRNAs and the development of radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients who underwent radiotherapy, and develop a predictive model for symptomatic radiation pneumonitis (SRP) by integrating miRNA expression levels with clinical and dosimetric parameters. Methods: A total of 95 NSCLC patients, who were scheduled to receive definitive radiotherapy, were prospectively enrolled. Plasma exosomes were collected before the radiotherapy, and high-throughput sequencing followed by bioinformatics analysis was performed to identify the candidate miRNAs associated to SRP. Then, the expression levels of these miRNAs were validated using RT-qPCR. Afterwards, a predictive model for SRP was constructed using a nomogram, which combined the miRNA expression data with the clinical and dosimetric factors. Results: Among the 95 patients, 20 (21.10%) patients developed SRP. The high-throughput sequencing revealed 220 differentially expressed miRNAs. Among these miRNAs, 168 miRNAs were upregulated and 52 miRNAs were downregulated in SRP patients (p<0.05). The bioinformatics analysis identified miR-200b-5p as the key candidate miRNA. The univariate and multivariate analyses revealed that lung V5 (OR: 1.264, 95% CI: 1.042-1.532, p=0.018), mean lung dose (MLD; OR: 1.013, 95% CI: 1.004-1.023, p=0.006), and miR-200b-5p expression (OR: 0.144, 95% CI: 0.024-0.877, p=0.032) were the independent risk factors for SRP. The nomogram model that incorporated these factors achieved an area under the receiver operating characteristic curve (AUC) of 0.844, outperforming the individual factors alone (lung V5: 0.748, MLD: 0.760, and miR-200b-5p expression: 0.666). Conclusion: The combination of lung V5 >46.36%, MLD >1120 cGy, and miR-200b-5p expression <0.445 can be used to effectively predict the occurrence of SRP in locally advanced NSCLC patients. This model can aid in the early identification of patients at high risk for RP, allowing for personalized treatment adjustments and improved patient outcomes.
Keywords: exosomal miRNAs, radiation pneumonitis (RP), Non-small cell lung cancer (NSCLC), predictive model, miR-200b-5p
Received: 24 Oct 2024; Accepted: 04 Aug 2025.
Copyright: © 2025 Zhai, Zhu, Wang, Zhao, Liang, Que, Dai, Wang, Li, Yang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Feng, Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.